Trevi Therapeutics’ Q4 2024 Earnings Call: A Charming Chat with Jennifer Good and Lisa Delfini
On a crisp afternoon of March 18, 2025, Trevi Therapeutics, Inc. (NASDAQ: TRVI) graciously invited investors, analysts, and the curious public to partake in their Fourth Quarter and Year End 2024 Earnings Conference Call. The call was brimming with charm and personality, as Co-Founder, President, and Chief Executive Officer, Jennifer Good, and Chief Financial Officer, Lisa Delfini, regaled us with updates on the company’s latest achievements and future plans.
Warm Welcomes and Introductions
“Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call,” Jennifer Good began, her voice as inviting as a warm cup of cocoa on a cold winter day. “I’m Jennifer Good, your Co-Founder, President, and Chief Executive Officer, and this is Lisa Delfini, our Chief Financial Officer. We’re thrilled to have you all join us today as we discuss our latest financial results and business developments.”
Company Participants Share Exciting Updates
Jennifer Good: “Let me begin by sharing some of our recent accomplishments. In the last quarter, we successfully completed our Phase 2b clinical trial for our lead product, TV-45070, which is a potential treatment for primary sclerosing cholangitis. We’re pleased to report that the trial met its primary and secondary endpoints, demonstrating significant improvements in clinical response and biochemical response in patients. We’re currently preparing to submit an NDA for TV-45070 to the FDA and expect a response by the end of the year.”
Lisa Delfini: “Jennifer and I are also excited to share that we’ve secured a strategic partnership with Merck KGaA for the commercialization of TV-45070 in Europe. This collaboration will allow us to expand our reach and make a difference in the lives of more patients. In terms of our financials, we reported a net loss of $13.2 million for the quarter, which was primarily driven by R&D expenses related to our clinical trials. However, we ended the year with $125 million in cash, providing us with ample resources to continue our research and development efforts.”
Analysts Ask Thoughtful Questions
Faisal Khurshid from Leerink Partners: “Jennifer and Lisa, congratulations on the successful completion of the Phase 2b trial. Could you provide some insights into the next steps in the development process for TV-45070?”
Jennifer Good: “Absolutely, Faisal. We’ll be working closely with the FDA to prepare our NDA submission, and we anticipate a response by the end of the year. Once we receive approval, we’ll begin commercializing TV-45070 in the United States. As for our European partnership with Merck KGaA, they’ll be responsible for the commercialization of TV-45070 in Europe, and we expect to see launches in key European markets in 2026.”
Impact on Individuals and the World
The success of Trevi Therapeutics’ clinical trial for TV-45070 is a promising development for individuals living with primary sclerosing cholangitis, a debilitating liver condition. The treatment, if approved, could significantly improve the lives of these patients by reducing symptoms and potentially preventing complications. Furthermore, the partnership with Merck KGaA will allow TV-45070 to reach a larger audience, making a difference in the lives of more people.
On a larger scale, the success of Trevi Therapeutics’ clinical trial and partnership demonstrates the power of innovation and collaboration in the pharmaceutical industry. It serves as an inspiration for other companies to continue investing in research and development, ultimately leading to the creation of new treatments and cures for various diseases.
Conclusion
“In conclusion, we’re thrilled with the progress we’ve made in the past year and are excited about the future. Our successful clinical trial for TV-45070, our partnership with Merck KGaA, and our strong financial position provide us with a solid foundation for continued growth and innovation. We’re grateful for the support of our investors, analysts, and the entire Trevi Therapeutics community, and we look forward to making a difference in the lives of patients with primary sclerosing cholangitis. Thank you all for joining us today, and we look forward to updating you on our progress in the coming months.”
- Trevi Therapeutics reports successful completion of Phase 2b clinical trial for TV-45070
- NDA submission to FDA anticipated by end of 2025
- Strategic partnership with Merck KGaA for commercialization in Europe
- Net loss of $13.2 million for Q4 2024, $125 million in cash
- Impact on individuals: potential improvement in quality of life for primary sclerosing cholangitis patients
- Impact on the world: demonstrates power of innovation and collaboration in the pharmaceutical industry
